1. DOP80 Integrated tissue transcriptomic and serum proteomic interrogation reveals biomarkers for endoscopic improvement and histologic remission after JAK3/TEC inhibition in Ulcerative Colitis (UC) (Phase 2b Vibrato study). (21st January 2022) Authors: Hassan-Zahraee PhD, M; Ye, Z; Xi, L; Banerjee, A; He, W; Dushin, E; Lee, J; Altintas, E; Romatowski, J; Leszczyszyn, J; Danese, S; Sandborn, W J; Banfield, C; Gale, J; Peeva, E; Vincent, M; Hyde, C; Longman, R; Hung, K E Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i124 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP33 Oral ritlecitinib and brepocitinib in patients with Moderate to Severe Active Ulcerative Colitis: Data from the VIBRATO umbrella study. (27th May 2021) Authors: Sandborn, W; Danese, S; Leszczyszyn, J; Romatowski, J; Altintas, E; Peeva, E; Vincent, M; Reddy, P; Banfield, C; Banerjee, A; Gale, J; Hung, K Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S030 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗